199 related articles for article (PubMed ID: 33990545)
1. Therapeutic potential of targeting membrane-spanning proteoglycan SDC4 in hepatocellular carcinoma.
Yang H; Liu Y; Zhao MM; Guo Q; Zheng XK; Liu D; Zeng KW; Tu PF
Cell Death Dis; 2021 May; 12(5):492. PubMed ID: 33990545
[TBL] [Abstract][Full Text] [Related]
2. Na+/K+-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin.
Li H; Wang P; Gao Y; Zhu X; Liu L; Cohen L; Meng Z; Yang P
Oncol Rep; 2011 Mar; 25(3):825-30. PubMed ID: 21181095
[TBL] [Abstract][Full Text] [Related]
3. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways.
Chen YY; Lu HF; Hsu SC; Kuo CL; Chang SJ; Lin JJ; Wu PP; Liu JY; Lee CH; Chung JG; Chang JB
Environ Toxicol; 2015 Jan; 30(1):74-82. PubMed ID: 23949904
[TBL] [Abstract][Full Text] [Related]
4. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
[TBL] [Abstract][Full Text] [Related]
5. Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway.
Yang Z; Tao Y; Xu X; Cai F; Yu Y; Ma L
Biochem Biophys Res Commun; 2018 Sep; 503(3):2124-2131. PubMed ID: 30100060
[TBL] [Abstract][Full Text] [Related]
6. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of syndecan-4 protein expression in colorectal cancer.
Jechorek D; Haeusler-Pliske I; Meyer F; Roessner A
Pathol Res Pract; 2021 Jun; 222():153431. PubMed ID: 34029877
[TBL] [Abstract][Full Text] [Related]
8. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway.
Gai JQ; Sheng X; Qin JM; Sun K; Zhao W; Ni L
Int J Oncol; 2016 Jan; 48(1):338-48. PubMed ID: 26648168
[TBL] [Abstract][Full Text] [Related]
9. Effects of syndecan-4 gene silencing by micro RNA interference in anoikis resistant endothelial cells: Syndecan-4 silencing and anoikis resistance.
Onyeisi JOS; Pernambuco Filho PCA; Mesquita APS; Azevedo LC; Nader HB; Lopes CC
Int J Biochem Cell Biol; 2020 Nov; 128():105848. PubMed ID: 32927086
[TBL] [Abstract][Full Text] [Related]
10. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
11. RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.
Deng Q; Li KY; Chen H; Dai JH; Zhai YY; Wang Q; Li N; Wang YP; Han ZG
Hepatology; 2014 Feb; 59(2):518-30. PubMed ID: 23929653
[TBL] [Abstract][Full Text] [Related]
12. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP.
Chen Y; Liu JM; Xiong XX; Qiu XY; Pan F; Liu D; Lan SJ; Jin S; Yu SB; Chen XQ
Oncotarget; 2015 Mar; 6(8):6406-21. PubMed ID: 25788268
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-4 in Tumor Cell Motility.
Keller-Pinter A; Gyulai-Nagy S; Becsky D; Dux L; Rovo L
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282767
[TBL] [Abstract][Full Text] [Related]
14. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition action of bufalin on human transplanted hepatocellular tumor and its effects on expressions of Bcl-2 and Bax proteins in nude mice].
Gu W; Han KQ; Su YH; Huang XQ; Ling CQ
Zhong Xi Yi Jie He Xue Bao; 2007 Mar; 5(2):155-9. PubMed ID: 17352871
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice.
Han KQ; Huang G; Gu W; Su YH; Huang XQ; Ling CQ
World J Gastroenterol; 2007 Jun; 13(24):3374-9. PubMed ID: 17659679
[TBL] [Abstract][Full Text] [Related]
19. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
Oncotarget; 2017 Jan; 8(5):7489-7501. PubMed ID: 27283490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
